The production of estrogen due to the action of the aromatase enzyme enhances tumor cell growth in hormone-dependent breast cancer, therefore aromatase inhibitors, such as letrozole, have been used clinically for the treatment of this type of cancer (see Reference [155] for a review of the use of aromatase inhibitors in breast cancer). Here, CYP19A1 is linked to breast carcinoma.